Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2007

Ikaria and Investor Group to Acquire INO Therapeutics for $670M

  • Ikaria Holdings will merge with INO Therapeutics in a transaction valued at approximately $670 million.

    INO Therapeutics is being acquired from The Linde Group, which will retain an equity position in the new entity. The combined company, which will be called Ikaria Holdings, will focus on therapeutic gases and critical care medicine. Its corporate headquarters will be in Clinton, NJ.

    "The merger of Ikaria and INO Therapeutics creates a fully integrated critical care therapeutics company with more than 300 employees, exceptional growth opportunities, and the capability to significantly improve critical care for newborns and other patients in thousands of hospitals around the world," says David Shaw, chairman and CEO-designate of the combined Ikaria entity.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »